抗体-药物偶联物在晚期胃癌中的应用现状与进展  

The application and progress of antibody-drug conjugate in advanced gastric cancer

作　　者：吴紫瑶 马继春[1] 祝成楼 达明绪 WU Ziyao;MA Jichun;ZHU Chenglou;DA Mingxu(The First Clinical Medical College of Lanzhou University,Lanzhou 730000,P.R.China)

机构地区：[1]兰州大学第一临床医学院,兰州730000

出　　处：《中国普外基础与临床杂志》2023年第11期1372-1377,共6页Chinese Journal of Bases and Clinics In General Surgery

基　　金：国家自然科学基金资助项目(项目编号:82160588)。

摘　　要：目的总结抗体-药物偶联物(antibody-drug conjugate,ADC)在胃癌中的作用及临床意义的研究进展。方法回顾近年来国内外关于ADC在胃癌中的相关研究进展并进行归纳总结。结果ADC正在成为晚期胃癌患者最有效的治疗手段之一,ADC的使用为晚期胃癌患者的治疗和预后带来了显著影响,但同时它们在临床中的应用也在某些方面具有局限性。目前有靶向人表皮生长因子受体2、人表皮生长因子受体3、鸟苷酸环化酶C和人滋养细胞表面抗原2的ADC。开发具有多种作用机制的ADC具有广阔前景。结论ADC药物是一种有价值的胃癌治疗手段,有望为胃癌患者的治疗带来新的思路与视角。Objective This study aims to summarize the application and research progress of antibody-drug conjugates(ADC)in gastric cancer(GC).Method We reviewed recent domestic and international research on ADC in GC and conducted a comprehensive summary.Results ADC was emerging as one of the most effective therapeutic options for advanced GC patients,significantly impacting the treatment and prognosis of these patients.However,their clinical application had certain limitations in some aspects.There were some kinds of ADC targeting human epidermal growth factor receptor-2,human epidermal growth factor receptor-3,guanylyl cyclase C,and trophoblasti surface antigen 2.Furthermore,the development of ADC with multiple mechanisms of action held great promise.Conclusion ADC drugs represent a valuable approach for the treatment of GC and offer new perspectives and insights into the management of GC patients.

关 键 词：胃癌 抗体-药物偶联物 机制 治疗 

分 类 号：R735.2[医药卫生—肿瘤]